@article{7a1a663b5dd446bbb008cb671437317c,
title = "Regularized regression on compositional trees with application to MRI analysis",
abstract = "A compositional tree refers to a tree structure on a set of random variables where each random variable is a node and composition occurs at each non-leaf node of the tree. As a generalization of compositional data, compositional trees handle more complex relationships among random variables and appear in many disciplines, such as brain imaging, genomics and finance. We consider the problem of sparse regression on data that are associated with a compositional tree and propose a transformation-free tree-based regularized regression method for component selection. The regularization penalty is designed based on the tree structure and encourages a sparse tree representation. We prove that our proposed estimator for regression coefficients is both consistent and model selection consistent. In the simulation study, our method shows higher accuracy than competing methods under different scenarios. By analysing a brain imaging data set from studies of Alzheimer's disease, our method identifies meaningful associations between memory decline and volume of brain regions that are consistent with current understanding.",
keywords = "composition, hierarchical tree, regularized regression",
author = "{for the Alzheimer's Disease Neuroimaging Initiative*} and Bingkai Wang and Caffo, {Brian S.} and Xi Luo and Liu, {Chin Fu} and Faria, {Andreia V.} and Miller, {Michael I.} and Yi Zhao",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH‐12‐2‐0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This work was supported by NIH grants (P30AG072976, U54AG065181, R01EB029977, P41EB031771, and U54DA049110). Publisher Copyright: {\textcopyright} 2022 Royal Statistical Society.",
year = "2022",
month = jun,
doi = "10.1111/rssc.12545",
language = "English (US)",
volume = "71",
pages = "541--561",
journal = "Journal of the Royal Statistical Society. Series C: Applied Statistics",
issn = "0035-9254",
publisher = "Wiley-Blackwell",
number = "3",
}